Two members of an FDA advisory committee quit after approval of controversial Alzheimer’s drug

The FDA decision to approve Aduhelm set off a firestorm because critics say there is scant evidence the drug is effective.

Read the full post at Health
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive